논문검색
Author In Sil Choi, M.D., Ph.D.1,2, Do-Youn Oh, M.D., Ph.D.1,2, Byoung-Su Kim, M.D.1,2, Keun-Wook Lee, M.D., Ph.D.1,3, Jee Hyun Kim, M.D., Ph.D.1,3 and Jong-Seok Lee, M.D., Ph.D.1,3
Place of duty 1Cancer Research Institute, Seoul National University College of Medicine, 2Department of Internal Medicine, Seoul Municipal Boramae Hospital, Seoul, 3Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
Title Oxaliplatin, 5-FU, Folinic Acid as First-line Palliative Chemotherapy in Elderly Patients with Metastatic or Recurrent Gastric Cancer
Publicationinfo Cancer Res Treat 2007 Sep; 039(03): 99-103.
Key_word Stomach neoplasms, Elderly, Chemotherapy, Oxaliplatin
Full-Text
Abstract Purpose: We investigated the efficacy and safety of a combination of oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) as first-line palliative chemotherapy for elderly patients with metastatic or recurrent gastric cancer. Materials and Methods: The study patients were chemotherapy-naive patients (＞ 65 years old) with histologically confirmed, metastatic or recurrent gastric cancer. Chemotherapy consisted of oxaliplatin 100 mg/m2 and FA 100 mg/m2 (2-hour infusion), and then 5-FU 2400 mg/m2 (46-hour continuous infusion) every 2 weeks. Results: A total of 37 patients were studied between April 2004 and October 2006. Of the 34 evaluable patients, none achieved a complete response (CR) and 14 achieved a partial response (PR), resulting in an overall response rate of 41.2%. The median time to progression (TTP) was 5.7 months (95% CI: 4.2∼6.3 months) and the median overall survival (OS) was 9.8 months (95% CI: 4.4∼12.0 months). The main hematologic toxicities were anemia and neutropenia, which were observed in 56.7% and 32.4% of the patients, respectively. Grade 3/4 neutropenia was observed in 8.1% of the patients. None of the patients experienced febrile neutropenia. Peripheral neuropathy occurred in 35.1% of the patients and all were grade 1/2. Conclusion: This oxaliplatin/5-FU/FA regimen showed good efficacy and an acceptable toxicity profile in elderly patients with metastatic or recurrent gastric cancer. (Cancer Res Treat. 2007;39:99-103)
출판정보 대한암학회지 2007 Sep; 039(03): 99-103.